Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William R Spreen

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
AIDS (London, England)|October 15, 2021
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapyAnthony Mills, Gary J Richmond, Cheryl Newman, et al.
Journal of the International AIDS Society|September 13, 2022
Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness studyCindy P Garris, Maggie Czarnogorski, Marybeth Dalessandro, et al.
Clinical Pharmacology in Drug Development|April 29, 2025
A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High-Concentration, Long-Acting Cabotegravir Formulation in Adults Without HIVKelong Han, Paul Benn, Jörg Sievers, et al.
Journal of the International AIDS Society|September 12, 2022
Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE)Maggie Czarnogorski, Cindy P Garris, Marybeth Dalessandro, et al.
British Journal of Clinical Pharmacology|June 13, 2022
Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjectsKelong Han, Mark Baker, Mark Lovern, et al.
Science Translational Medicine|January 16, 2015
A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challengeChasity D Andrews, Yun Lan Yueh, William R Spreen, et al.
HIV Medicine|November 22, 2022
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trialsParul Patel, Susan L Ford, Mark Baker, et al.
The Lancet. HIV|October 17, 2021
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR studyChloe Orkin, Enrique Bernal Morell, Darrell H S Tan, et al.
The Lancet. Infectious Diseases|July 24, 2015
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trialDavid A Margolis, Cynthia C Brinson, Graham H R Smith, et al.
AIDS (London, England)|July 14, 2021
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatmentSusan Swindells, Thomas Lutz, Lelanie Van Zyl, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
AIDS (London, England)|October 15, 2021
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapyAnthony Mills, Gary J Richmond, Cheryl Newman, et al.
Journal of the International AIDS Society|September 13, 2022
Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness studyCindy P Garris, Maggie Czarnogorski, Marybeth Dalessandro, et al.
Clinical Pharmacology in Drug Development|April 29, 2025
A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High-Concentration, Long-Acting Cabotegravir Formulation in Adults Without HIVKelong Han, Paul Benn, Jörg Sievers, et al.
Journal of the International AIDS Society|September 12, 2022
Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE)Maggie Czarnogorski, Cindy P Garris, Marybeth Dalessandro, et al.
British Journal of Clinical Pharmacology|June 13, 2022
Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjectsKelong Han, Mark Baker, Mark Lovern, et al.
Science Translational Medicine|January 16, 2015
A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challengeChasity D Andrews, Yun Lan Yueh, William R Spreen, et al.
HIV Medicine|November 22, 2022
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trialsParul Patel, Susan L Ford, Mark Baker, et al.
The Lancet. HIV|October 17, 2021
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR studyChloe Orkin, Enrique Bernal Morell, Darrell H S Tan, et al.
The Lancet. Infectious Diseases|July 24, 2015
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trialDavid A Margolis, Cynthia C Brinson, Graham H R Smith, et al.
AIDS (London, England)|July 14, 2021
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatmentSusan Swindells, Thomas Lutz, Lelanie Van Zyl, et al.
Pageof 5